Yet, as many have observed, an industry that should be hailed as one of the greatest contributors to health in our society actually ranks among the lowest in public trust. When I read this article, I didn’t know whether to be cynical or cheer – and it was more than just the article, it was […]
I haven’t yet fully watched Tony Blair’s second round of Testimony before the Chilcot Inquiry at the end of last week, but I wanted to comment on the 03/17/2002 Memo released right before this testimony. THE EARLY ROAD TO IRAQ 03/17/2002 BLAIR’S MEMO TO JOHNATHAN POWELL [see below]. Blair’s reflections on how to sell […]
Daughter Abby in 1980, in 1988 at Oberlin, and last weekend opening with her band, Cloudlines, in Raleigh. Same face, same guitar, same great voice…
[AKA a rant] In the late 1960s, I was an Intern then Resident in Internal Medicine at a large Charity Hospital in the South – one of those places where it seemed like every patient was desperately ill [in the local parlance – "low sick"]. And the problem of being a young doctor was that […]
I thought I could put Drs. Schatzberg and Nemeroff on the side for a while after a few days with Corcept, but up they bounced when I read the article below. I’ll have to admit, it’s a classic. Remember back in late November, POGO wrote a letter to Dr. Francis Collins, Director of the NIH, […]
I’ve only done one other "Series" like this as a blogger. It was about Deregulation and it was because I just didn’t get what had happened when our economy collapsed. It’s my way of learning about something that baffles me. I left academic psychiatry back in the days when all this biology came into our […]
I skipped over some things because my real interest is the corruption of Academic medicine, not so much in the spin and grin of a start-up pharmaceutical company. By the end of 2006 with two failed clinical Phase III clinical trials, Corcept was in trouble. They published a study that I think had been done […]
While there are more things to say about Corcept and Mifepristone, I’ll save them for later and move to the center ring. In the years before 2008, there had been a growing outcry about the widespread Conflicts of Interest involving Academic Medicine’s ties to the Pharmaceutical Industry – blogs, newspaper articles, exposé literature, letters to […]
Corcept did indeed go public in the Spring of 2004, selling shares worth over $50 M. In September of 2005, the Stanford group published a third Mifepristone study online [in print in on March 2006]. At the time, Dr. Charles Nemeroff was the editor of Neuropsychopharmacology [the Journal that published the study]. His editorship ended […]